ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy] ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q4 2023
0
Period ended Dec 31, 2023
Change on a year earlier
-100.0%
38 in Q4 2022
History
16 quarters
Since Q1 2020
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 38 | -96.3% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 387 | +79.4% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 129 | +54.8% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,455 | +123.7% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,029 | +21.0% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 216 | – | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 83.4 | – | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 651 | – | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 850 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | – | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 0 | – | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | – | Form 10-Q (filed 2021-04-30) ↗ |
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy] ($M), quarterly Q1 2020–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_covid19antibodies_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.